Compare BBU & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BBU | ADPT |
|---|---|---|
| Founded | 2016 | 2009 |
| Country | Bermuda | United States |
| Employees | N/A | N/A |
| Industry | Engineering & Construction | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 2.3B |
| IPO Year | 2015 | 2019 |
| Metric | BBU | ADPT |
|---|---|---|
| Price | $31.46 | $14.11 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 9 |
| Target Price | ★ $39.40 | $17.78 |
| AVG Volume (30 Days) | 48.7K | ★ 1.9M |
| Earning Date | 05-01-2026 | 05-05-2026 |
| Dividend Yield | ★ 0.79% | N/A |
| EPS Growth | N/A | ★ 63.89 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $276,976,000.00 |
| Revenue This Year | N/A | $3.98 |
| Revenue Next Year | N/A | $22.72 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 54.77 |
| 52 Week Low | $19.91 | $6.77 |
| 52 Week High | $37.75 | $20.76 |
| Indicator | BBU | ADPT |
|---|---|---|
| Relative Strength Index (RSI) | 44.87 | 49.46 |
| Support Level | $29.90 | $12.19 |
| Resistance Level | $36.93 | $17.72 |
| Average True Range (ATR) | 1.38 | 0.98 |
| MACD | 0.23 | 0.14 |
| Stochastic Oscillator | 46.92 | 58.46 |
Brookfield Business Partners LP is a business services and industrials company. It focused on operating businesses that are either low-cost producers and benefit from high barriers to entry. The company's operating segment includes Business services; Infrastructure services; Industrials and Corporate and other. It generates maximum revenue from the Business Services segment. Geographically operates in USA, Europe, Australia, Brazil, Canada, UK, Mexico and Other, majority of revenue is from UK.
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.